Ezetimibe: Indication, Dosage, Side Effect, Precaution

Generic Medicine Info Patient Medicine Information

This information is not country-specific. Please refer to the Myanmar prescribing information.

Generic Medicine Info

Indications and Dosage

Oral
Homozygous familial sitosterolaemia, Hyperlipidaemias

Adult: 10 mg once daily.
Child: ≥10 yr Same as adult dose.

Administration

May be taken with or without food.

Special Precautions

Exclude or treat secondary causes of dyslipidaemia prior to initiating therapy. Renal and hepatic impairment. Pregnancy and lactation.

Adverse Reactions

Headache, abdominal pain, diarrhoea, fatigue, chest pain, arthralgia, myalgia, anaphylaxis, erythema multiforme, angioedema, rash, and urticaria. Rarely, raised liver enzymes or hepatitis, pancreatitis, thrombocytopenia, cholelithiasis, cholecystitis, raised creatine kinase, myopathy, and rhabdomyolysis.

Pregnancy Category (US FDA)

PO: C

Monitoring Parameters

Monitor total cholesterol profile prior to therapy and periodically thereafter.

Drug Interactions

Reduced absorption w/ colestyramine. Increased plasma concentrations w/ ciclosporin. Concomitant use w/ oral anticoagulants may result in increased INR.

Action

Description: Ezetimibe localises at the brush border of the small intestine and inhibits absorption of cholesterol via the sterol transporter, Niemann-Pick C1-Like1 (NPC1L1). This results in decreased delivery of cholesterol to the liver, reduction of hepatic cholesterol stores and increased clearance of cholesterol from the blood.
Pharmacokinetics:
Absorption: Rapidly absorbed. Time to peak plasma concentration: 4-12 hr.
Distribution: Plasma protein binding: >90%.
Metabolism: Undergoes extensive conjugation in small intestine and liver to form an active glucuronide metabolite; may also undergo enterohepatic recycling.
Excretion: Via bile in the faeces (approx 78% mainly as unchanged drug); urine (approx 11% mainly as metabolite). Elimination half-life: Approx 22 hr.

Chemical Structure

Storage

Store at 25°C. Protect from moisture.

MIMS Class

Dyslipidaemic Agents

References

Anon. Ezetimibe. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 07/10/2014.

Buckingham R (ed). Ezetimibe. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 07/10/2014.

Joint Formulary Committee. Ezetimibe. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 07/10/2014.

McEvoy GK, Snow EK, Miller J et al (eds). Ezetimibe. AHFS Drug Information (AHFS DI) [online]. American Society of Health-System Pharmacists (ASHP). https://www.medicinescomplete.com. Accessed 07/10/2014.

Zetia Tablet (Merck Sharp & Dohme Corp.). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 07/10/2014.

Zetia Tablets. U.S. FDA. https://www.fda.gov. Accessed 07/10/2014.

Disclaimer: This information is independently developed by MIMS based on Ezetimibe from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2024 MIMS. All rights reserved. Powered by MIMS.com